End-stage Renal Disease Clinical Trial
Official title:
Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration? Feasibility Study in Preparation of the Convective Transport Study (CONTRAST II)
Two recent randomized controlled trials (RCT) on online hemodiafiltration (HDF) did not show
a treatment effect on patient survival when compared with low‐ or high‐flux hemodialysis.
Interestingly, post‐hoc (on treatment) analyses from both trials unequivocally showed
reduced mortality in the patient group achieving the highest convection volumes. Moreover, a
third trial recently found a significant 30% decrease in mortality when HDF was applied with
a mean convection volume of 23.7 L per session, which was somewhat higher than the average
volumes reached in the aforementioned trials. Altogether, these findings support the concept
of a dose-response effect, in which a minimally delivered convection volume is required in
order to show a survival benefit.
Hence, the question arises whether high convection volumes are achievable in the majority of
patients. The aim of this study is thus to test the following hypothesis: high‐volume (>22
liters per treatment) post-dilution on‐line hemodiafiltration (HDF) is achievable in the
majority (>75%) of patients treated with chronic intermittent hemodialysis. This will be
done through the use of a dedicated standardized protocol, in which the three most important
determinants of convection volume will be successively optimized: treatment time, blood flow
rate and filtration fraction.
Hemodialysis (HD) is the most common used renal replacement therapy worldwide. The main
objective is the removal of excess fluid and toxic solutes from the patient. Despite the
relative efficiency of modern dialyzers, HD remains inferior to normal kidney function, in
part because of the inadequate clearance of so-called 'middle molecules'. In other words,
'uremic toxins' accumulate in chronic HD patients.
The role of middle molecular weight uremic toxins in the pathogenesis of many co-morbid
conditions associated with end-stage renal disease is increasingly recognized. Hence, the
hypothesis that their enhanced removal could convey a better survival has been proposed.
Actually, HDF is the most effective modality in terms of solute removal, because solute
transport is achieved by both diffusion (especially for small molecules) and convection (the
most important clearance route for middle molecules). Although some convective transport can
be achieved with high-flux HD, only in HDF can the amount of filtered volume reach values of
20 liters per session or more.
In line with this thinking, two RCTs comparing HDF to standard hemodialysis with either low-
or high-flux membranes were performed. However, treatment assignment did not alter the
primary outcome of all-cause mortality in neither of them. Interestingly, post‐hoc analyses
from both trials unequivocally showed reduced mortality in the patient group achieving the
highest convection volumes. Whether these data result from so‐called dose-targeting bias
(the healthiest patients reaching the highest volumes) cannot be formally excluded, but it
is noteworthy that these results remained after correction for known determinants of
mortality. Moreover, careful examination of patients' baseline characteristics of the
CONTRAST HDF cohort did not reveal a healthier profile among the high convection volume
group.
Recently, a third trial found a significant 30% decrease in mortality when HDF was applied
with a mean convection volume of 23.7 L per session, which was somewhat higher than the
average volumes reached in the aforementioned trials (respectively 20.7 and 19.5 L per
session). Altogether, these findings support the concept of a dose-response effect, in which
a minimally delivered convection volume is required in order to show a survival benefit.
Hence, the question arises whether high convection volumes are achievable in the majority of
patients. In a previous sub-analysis of CONTRAST, it was found that the most important
determinants of achieved convection volume were treatment time and blood flow rate.
Moreover, it was noted that convection volumes and filtration fraction (defined as the ratio
of extracted plasma water flow rate to blood flow rate) differed markedly per participating
center, suggesting different practice patterns. Thus, it is plausible that the optimization
of these apparently seemingly modifiable factors, on an individual basis through a dedicated
standardized protocol, could translate into a higher achieved convection volume.
The aim of this study is to test the following hypothesis: high‐volume (>22 liters per
treatment) post-dilution on‐line hemodiafiltration (HDF) is achievable in the majority
(>75%) of patients treated with chronic intermittent hemodialysis.
This study is a prospective observational study, in which all enrolled patients will be
treated by post-dilution on-line HDF with the application of a standardized protocol aiming
at maximizing the convection volume.
At the beginning of the study, each patient's usual dialysis parameters will serve as
starting parameters. In addition, incident HDF patients will start with a filtration
fraction of 25 % (or equivalent) on a post‐dilution mode.
Then, convection volume will be increased stepwise by successively optimizing the three most
important determining factors. First, treatment time will be increased to 4 h, if possible.
Second, blood flow will be increased by 50 mL/min per treatment until a value 400 mL/min is
reached, provided that pre-specified safety limits are respected. Third, filtration fraction
will be increased by 2% per treatment up to a maximum of 33% or the maximally achieved value
within safety limits. To take into account different settings between the various dialysis
machines used by the participating centers, an easy-to-use conversion table will be provided
to the nursing staff, allowing to find the parameter (substitution flow, substitution volume
or substitution ratio) corresponding to the desired filtration fraction.
At the end of the step-up protocol, the achieved convection volume will be assessed and
compared to the starting value. Additionally, a follow-up period of 8 weeks, in which the
maximum values of the targeted parameters will be kept the same, will be observed in order
to assess whether the high convective volumes can be maintained for a longer period.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04087213 -
Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
|
N/A | |
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT02237521 -
The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease
|
N/A | |
Withdrawn |
NCT01691196 -
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
|
||
Completed |
NCT01394341 -
Liraglutide Treatment to Patients With Severe Renal Insufficiency
|
Phase 4 | |
Active, not recruiting |
NCT00247507 -
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00307463 -
Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation
|
Phase 4 | |
Recruiting |
NCT00155363 -
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
|
Phase 4 | |
Completed |
NCT00234156 -
The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers
|
N/A | |
Completed |
NCT00586131 -
Arterial pH and Total Body Nitrogen Balances in APD
|
Phase 4 | |
Active, not recruiting |
NCT05027074 -
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
|
Phase 2 | |
Recruiting |
NCT04575077 -
The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
|
||
Enrolling by invitation |
NCT05001009 -
Goals of Care Conversations Study
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Recruiting |
NCT03862859 -
The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis
|
Phase 4 | |
Terminated |
NCT03661229 -
Cardiovascular and Respiratory Assessment Using Biometric Signals in a Non-contact Monitoring Device
|
N/A | |
Completed |
NCT03288922 -
Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF
|
N/A | |
Completed |
NCT02360748 -
A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT02572882 -
Gut Microbiome and p-Inulin in Hemodialysis
|
N/A |